Several new therapies in development are designed to lower your IFN-1 levels, and the first IFN-1 lowering therapy was recently approved by the FDA for SLE patients with moderate to severe disease. Thus, hope is potentially on the horizon.

Know your IFN-1 Status

• More than 50% of SLE patients exhibit high IFN-1 activity¹
• SLE patients with elevated IFN-1 tend to have more active disease^1,2
• Increased risk of developing Lupus Nephritis³
• IFN-1 high patients may be at increased risk of developing preeclampsia during pregnancy⁴
• New IFN-1 lowering therapies may be an option^5-7